Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration

Nicole Bye, Mark Habgood, Jennifer Kay Callaway, N Malakooti, Ann Potter, Thomas K Kossmann, Maria Cristina Morganti-Kossmann

Research output: Contribution to journalArticleResearchpeer-review

160 Citations (Scopus)

Abstract

Cerebral inflammation and apoptotic cell death are two processes implicated in the progressive tissue damage that occurs following traumatic brain injury (TBI), and strategies to inhibit one or both of these pathways are being investigated as potential therapies for TBI patients. The tetracycline derivative minocycline was therapeutically effective in various models of central nervous system injury and disease, via mechanisms involving suppression of inflammation and apoptosis. We therefore investigated the effect of minocycline in TBI using a closed head injury model. Following TBI, mice were treated with minocycline or vehicle, and the effect on neurological outcome, lesion volume, inflammation and apoptosis was evaluated for up to 7 days. Our results show that while minocycline decreases lesion volume and improves neurological outcome at I day post-trauma, this response is not maintained at 4 days. The early beneficial effect is likely not due to anti-apoptotic mechanisms, as the density of apoptotic cells is not affected at either time-point. However, protection by minocycline is associated with a selective anti-inflammatory response, in that microglial activation and interleukin-1 beta expression are reduced, while neutrophil infiltration and expression of multiple cytokines are not affected. These findings demonstrate that further studies on minocycline in TBI are necessary in order to consider it as a novel therapy for brain-injured patients. Crown Copyright (c) 2006 Published by Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)220 - 233
Number of pages13
JournalExperimental Neurology
Volume204
Issue numberDec 2006
Publication statusPublished - 2007

Cite this

@article{3016b6732e924e48adcb9de920a83558,
title = "Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration",
abstract = "Cerebral inflammation and apoptotic cell death are two processes implicated in the progressive tissue damage that occurs following traumatic brain injury (TBI), and strategies to inhibit one or both of these pathways are being investigated as potential therapies for TBI patients. The tetracycline derivative minocycline was therapeutically effective in various models of central nervous system injury and disease, via mechanisms involving suppression of inflammation and apoptosis. We therefore investigated the effect of minocycline in TBI using a closed head injury model. Following TBI, mice were treated with minocycline or vehicle, and the effect on neurological outcome, lesion volume, inflammation and apoptosis was evaluated for up to 7 days. Our results show that while minocycline decreases lesion volume and improves neurological outcome at I day post-trauma, this response is not maintained at 4 days. The early beneficial effect is likely not due to anti-apoptotic mechanisms, as the density of apoptotic cells is not affected at either time-point. However, protection by minocycline is associated with a selective anti-inflammatory response, in that microglial activation and interleukin-1 beta expression are reduced, while neutrophil infiltration and expression of multiple cytokines are not affected. These findings demonstrate that further studies on minocycline in TBI are necessary in order to consider it as a novel therapy for brain-injured patients. Crown Copyright (c) 2006 Published by Elsevier Inc. All rights reserved.",
author = "Nicole Bye and Mark Habgood and Callaway, {Jennifer Kay} and N Malakooti and Ann Potter and Kossmann, {Thomas K} and Morganti-Kossmann, {Maria Cristina}",
year = "2007",
language = "English",
volume = "204",
pages = "220 -- 233",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Elsevier",
number = "Dec 2006",

}

Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. / Bye, Nicole; Habgood, Mark; Callaway, Jennifer Kay; Malakooti, N; Potter, Ann; Kossmann, Thomas K; Morganti-Kossmann, Maria Cristina.

In: Experimental Neurology, Vol. 204, No. Dec 2006, 2007, p. 220 - 233.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration

AU - Bye, Nicole

AU - Habgood, Mark

AU - Callaway, Jennifer Kay

AU - Malakooti, N

AU - Potter, Ann

AU - Kossmann, Thomas K

AU - Morganti-Kossmann, Maria Cristina

PY - 2007

Y1 - 2007

N2 - Cerebral inflammation and apoptotic cell death are two processes implicated in the progressive tissue damage that occurs following traumatic brain injury (TBI), and strategies to inhibit one or both of these pathways are being investigated as potential therapies for TBI patients. The tetracycline derivative minocycline was therapeutically effective in various models of central nervous system injury and disease, via mechanisms involving suppression of inflammation and apoptosis. We therefore investigated the effect of minocycline in TBI using a closed head injury model. Following TBI, mice were treated with minocycline or vehicle, and the effect on neurological outcome, lesion volume, inflammation and apoptosis was evaluated for up to 7 days. Our results show that while minocycline decreases lesion volume and improves neurological outcome at I day post-trauma, this response is not maintained at 4 days. The early beneficial effect is likely not due to anti-apoptotic mechanisms, as the density of apoptotic cells is not affected at either time-point. However, protection by minocycline is associated with a selective anti-inflammatory response, in that microglial activation and interleukin-1 beta expression are reduced, while neutrophil infiltration and expression of multiple cytokines are not affected. These findings demonstrate that further studies on minocycline in TBI are necessary in order to consider it as a novel therapy for brain-injured patients. Crown Copyright (c) 2006 Published by Elsevier Inc. All rights reserved.

AB - Cerebral inflammation and apoptotic cell death are two processes implicated in the progressive tissue damage that occurs following traumatic brain injury (TBI), and strategies to inhibit one or both of these pathways are being investigated as potential therapies for TBI patients. The tetracycline derivative minocycline was therapeutically effective in various models of central nervous system injury and disease, via mechanisms involving suppression of inflammation and apoptosis. We therefore investigated the effect of minocycline in TBI using a closed head injury model. Following TBI, mice were treated with minocycline or vehicle, and the effect on neurological outcome, lesion volume, inflammation and apoptosis was evaluated for up to 7 days. Our results show that while minocycline decreases lesion volume and improves neurological outcome at I day post-trauma, this response is not maintained at 4 days. The early beneficial effect is likely not due to anti-apoptotic mechanisms, as the density of apoptotic cells is not affected at either time-point. However, protection by minocycline is associated with a selective anti-inflammatory response, in that microglial activation and interleukin-1 beta expression are reduced, while neutrophil infiltration and expression of multiple cytokines are not affected. These findings demonstrate that further studies on minocycline in TBI are necessary in order to consider it as a novel therapy for brain-injured patients. Crown Copyright (c) 2006 Published by Elsevier Inc. All rights reserved.

UR - http://www.elsevier.com/locate/yexnr

M3 - Article

VL - 204

SP - 220

EP - 233

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - Dec 2006

ER -